top of page

AU-007 Immunotherapy for Advanced or Metastatic Cancer
A clinical trial for patients with melanoma, lung and other cancers
About the Clinical Trial
The AU-007 solid tumor study is an open label Phase 1/2 study evaluating the safety, tolerability and immunogenicity of AU-007 in patients with unresectable locally advanced or metastatic cancer. It is enrolling patients at multiple sites in the United States.
Cancer eligibility includes cutaneous melanoma and non-small cell lung cancer. Patients who have failed or progressed on anti-PD-1 or anti-PD-L1 therapy may be enrolled in the study.
Study Details

bottom of page